We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Simple Blood Test Monitors Compliance of Diabetic Patients

By LabMedica International staff writers
Posted on 17 Jun 2010
A simple blood test that checks whether diabetes is under control is now available. More...
The point-of-care test will enable physician to get results rapidly without the patient fasting.

The percentage of glycosalated hemoglobin (HbA1c) in the blood can now be measured with a hand held device that will give results in about three minutes. This will help physicians track a diabetic patient's glycemic control over the prior six to twelve week period.

The test, called the Avie A1c test, is an addition to HemoCue systems offered by Quest Diagnostics, (Quest Diagnostics Inc., Madison, NJ, USA) who have reached an agreement with MEC Dynamics (MEC Dynamics Corp, Santa Clara , CA, USA), to distribute it in the U.S. A. and Europe. The test is a more accurate way of testing diabetic patients' compliance with the treatment regime as HbA1c changes very slowly over a 10-12 week period, while glucose levels can vary daily.

HemoCue, with the addition of the Avie A1c test, will be able to offer a more complete suite of point-of-care (POC) tests for efficient diabetes management. Physicians can test for and diagnose the disease using the HemoCue Glucose 201 systems. They can monitor for diabetes-related complications with the HemoCue Albumin 201 test for microalbuminuria, a kidney and cardiovascular disease risk marker.

Jon R. Cohen, M.D., senior V.P. and chief medical officer at Quest Diagnostics said, "Having quality values at the point of care creates an opportunity for a physician to ask questions, discuss patient lifestyle, review medication history, and adjust treatment course as appropriate."

Diabetes is characterized by glucose intolerance and hyperglycemia. The latter represents a high level of glucose in the blood, which, if not properly monitored and managed, can lead to serious complications such as renal and cardiovascular disease. Diabetes was the seventh leading cause of death listed on U.S. death certificates in 2006, and it is estimated that about 8% of the U.S. and 7.8% European populations suffer from the disease.

Related Links:

Quest Diagnostics Inc.
MEC Dynamics Corp



Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automatic Western Blot Analyzer
Tenfly Phoenix Blot Analyzer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.